Antisense oligonucleotide therapy in diabetic retinopathy
about
RNA interference-based therapy for spinocerebellar ataxia type 7 retinal degeneration.In vivo delivery of cell-permeable antisense hypoxia-inducible factor 1α oligonucleotide to adipose tissue reduces adiposity in obese mice.Antisense technology: an emerging platform for cardiovascular disease therapeutics.In vitro and in vivo rescue of aberrant splicing in CEP290-associated LCA by antisense oligonucleotide delivery.The role of Raf-1 kinase in diabetic retinopathy.
P2860
Antisense oligonucleotide therapy in diabetic retinopathy
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on July 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Antisense oligonucleotide therapy in diabetic retinopathy
@en
Antisense oligonucleotide therapy in diabetic retinopathy.
@nl
type
label
Antisense oligonucleotide therapy in diabetic retinopathy
@en
Antisense oligonucleotide therapy in diabetic retinopathy.
@nl
prefLabel
Antisense oligonucleotide therapy in diabetic retinopathy
@en
Antisense oligonucleotide therapy in diabetic retinopathy.
@nl
P2093
P2860
P1476
Antisense oligonucleotide therapy in diabetic retinopathy
@en
P2093
David S Boyer
Ellen A Green
John G Clement
Lisa R Grillone
Peter Hnik
Scott P Henry
P2860
P304
P356
10.1177/193229680900300440
P577
2009-07-01T00:00:00Z